Literature DB >> 28363687

Conservative versus aggressive treatment strategy with angiographic guidance alone in patients with intermediate coronary lesions: The SMART-CASE randomized, non-inferiority trial.

Joo-Yong Hahn1, Seung-Hyuk Choi1, Jin-Ok Jeong2, Young Bin Song1, Jin-Ho Choi1, Yong Hawn Park3, Woo Jung Chun3, Ju Hyeon Oh3, Dae Kyoung Cho4, Seong-Hoon Lim5, Yu Jeong Choi6, Eul-Soon Im7, Kyung-Heon Won8, Sung Yun Lee9, Sang-Wook Kim10, Hyeon-Cheol Gwon11.   

Abstract

BACKGROUND: Although coronary angiography is still the technique most widely used to guide percutaneous coronary intervention (PCI), the appropriate angiographic indication of revascularization for intermediate coronary lesions remains controversial. The aim of this study was to compare conservative versus aggressive strategies with angiographic guidance alone in patients with intermediate coronary lesions. METHODS AND
RESULTS: A total of 899 patients with intermediate coronary lesions between 50% and 70% diameter stenosis by quantitative coronary analysis were randomly assigned to the conservative group (n=449) or the aggressive group (n=450). For intermediate lesions, PCI was performed using everolimus-eluting stents in the aggressive group, but was deferred in the conservative group. The primary end point was a composite of all-cause death, myocardial infarction, or any revascularization at 1year. The number of treated lesions per patient was 0.8±0.9 in the conservative group and 1.7±0.9 in the aggressive group (p<0.001). The cumulative rate of the primary endpoint was 7.3% in the conservative group and 6.8% in the aggressive group (the upper limit of the one-sided 95% confidence interval [CI], 3.4%; p=0.006 for non-inferiority with a predefined non-inferiority margin of 5.0%). The risk of death or myocardial infarction (hazard ratio [HR] 0.50; 95% CI, 0.19-1.33; p=0.17) and revascularization (HR 1.42; 95% CI, 0.80-2.52; p=0.23) was not significantly different between the 2 groups.
CONCLUSIONS: Conservative revascularization was non-inferior to aggressive revascularization for intermediate coronary lesions. Revascularization of intermediate lesions can be safely deferred in patients undergoing PCI with angiographic guidance alone. CLINICAL TRIAL REGISTRATION: URL: http://ClinicalTrials.gov. Unique identifier: NCT00743899.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Angiography; Stenting

Mesh:

Substances:

Year:  2017        PMID: 28363687     DOI: 10.1016/j.ijcard.2017.03.075

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  2 in total

1.  Prognostic value of N-terminal Pro-B-Type natriuretic peptide in patients with intermediate coronary lesions.

Authors:  Chenxi Song; Sheng Yuan; Kongyong Cui; Zhongxing Cai; Rui Zhang; Jining He; Zheng Qiao; Xiaohui Bian; Shaoyu Wu; Haoyu Wang; Rui Fu; Chunyue Wang; Qianqian Liu; Dong Yin; Lei Jia; Kefei Dou
Journal:  Front Cardiovasc Med       Date:  2022-07-28

2.  Impact of Arterial Remodeling of Intermediate Coronary Lesions on Long-Term Clinical Outcomes in Patients with Stable Coronary Artery Disease: An Intravascular Ultrasound Study.

Authors:  Liang Geng; Peizhao Du; Yuan Yuan; Liming Gao; Yunkai Wang; Jiming Li; Qi Zhang
Journal:  J Interv Cardiol       Date:  2021-06-11       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.